Search for a trial

Investigator led, double-masked, multicenter, randomized clinical trial for the comparison of Atropine 0.5% versus Atropine 0.05% eye drops for the prevention of myopia progression in Dutch children.

This study has been transitioned to CTIS with ID 2024-516379-34-00 check the CTIS register for the current data. Objectives:To compare the efficacy of Atropine 0.05% to Atropine 0.5% treatment in European children with progressive myopia, and to…

A Multicenter, Single-arm, Open-label, Extension, Rollover Study To Evaluate The Long-term Safety And Efficacy Of Ocrelizumab In Patients With Multiple Sclerosis

This study has been transitioned to CTIS with ID 2023-505974-14-00 check the CTIS register for the current data. Main objective:English To evaluate the longer-term safety of ocrelizumab in participants diagnosed with MS who were previously enrolled…

Trial Examining Methods for Antidepressant Discontinuation

This study has been transitioned to CTIS with ID 2024-511997-66-00 check the CTIS register for the current data. TEMPO will directly compare i) conventional 2-step reduction with ii) gradual tapering in patients with remitted MDD who use either the…

Gaining insight into dual sensory loss - Quantitative study

The objective of this study is to determine which problems arise from different levels of impairments in visual and auditory functions. We will especially focus on the areas of access to information, communication, fatigue and mobility.

A Phase 2/3, Randomized, Double-Blinded, Placebo-Controlled, Parallel-Group, 2-Arm, Multicenter, Operationally Seamless Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Participants Aged 18 Years and Older With Active Idiopathic Inflammatory Myopathy

This study has been transitioned to CTIS with ID 2024-512785-33-00 check the CTIS register for the current data. Primary objective: To evaluate the clinical improvement of efgartigimod PH20 SC treatment compared with placebo, in addition to standard…

A controlled, open-label post-authorisation efficacy and safety study in imlifidase desensitised kidney transplant patients with positive crossmatch against a deceased donor prior to imlifidase treatment, including non-comparative registry and concurrent reference cohorts

This study has been transitioned to CTIS with ID 2024-511810-18-00 check the CTIS register for the current data. Primary objective• To determine the 1-year graft failure-free survival in highly sensitised kidney transplant patients, pre-treated with…

A Phase 1b/2, Multicenter, Open-label Basket Study Evaluating the Safety and Efficacy of Bemarituzumab Monotherapy in Solid Tumors with FGFR2b Overexpression

This study has been transitioned to CTIS with ID 2023-505455-44-00 check the CTIS register for the current data. Part 1 (phase 1b)Primary:• To observe the safety and tolerability of bemarituzumabSecondary:• To evaluate preliminary antitumor activity…

Quinidine versus verapamil in short-coupled idiopathic ventricular fibrillation: An open label, randomized crossover pilot trial.

This study has been transitioned to CTIS with ID 2024-511190-30-00 check the CTIS register for the current data. To investigate the feasibility of a definitive RCT to assess the efficacy and safety of verapamil and quinidine in patients with short-…

Improving therapeutic ratio with hypofractionated stereotactic radiotherapy for brain metastases.

To determine if the incidence of adverse local events (local failure or radionecrosis) can be reduced with more than 20% using fSRT versus SRT in one or three fractions.

Pharmacokinetic-guided dosing of emicizumab in congenital haemophilia A patients - The DosEmi study

This study has been transitioned to CTIS with ID 2024-515528-35-00 check the CTIS register for the current data. Primary objectiveTo determine whether individualized pharmacokinetic (PK)-guided dosing of emicizumab is non-inferior to conventional…

An open-label, first-in-human, dose-escalation/expansion study of SAR443579 administered as single agent by intravenous infusion in adult and pediatric participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS) or blastic plasmacytoid dendritic cell neoplasm (BPDCN)

This study has been transitioned to CTIS with ID 2023-508357-58-00 check the CTIS register for the current data. The aim of the escalation portion of this study, in which SAR443579 is administered for the first time in humans, is to establish the…

LIMited wEdge ResectIon for Colonic T1 cancer - a prospective multicenter cohort study

The aim of this study is to investigate the safety and efficacy of CAL-WR as primary and curative colon-preserving treatment for T1 colon cancer. Our primary endpoint is reduction of oncologic resections for low-risk T1 colon cancer. As secondary…

EASYII - A Post-Market Clinical Follow-up Study (PMCF) in patients with infrarenal aortic aneurysm undergoing endovascular stenting with the E-tegra Stent Graft System - imaging cohort

To assess the stent stability and durability as well as the seal of the stent graft during the cardiac cycle and over time as well as to evaluate safety and clinical performance of the Etegra Stent Graft System used in endovascular treatment of…

A participant- and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants with idiopathic pulmonary fibrosis

This study has been transitioned to CTIS with ID 2023-508729-28-00 check the CTIS register for the current data. The purpose of the study is to look at how well the study treatment works in participants with idiopathic pulmonary fibrosis.

A Phase 3, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with Rituximab and Lenalidomide (R2) compared to R2 in Subjects with Relapsed or Refractory Follicular Lymphoma (EPCORE* FL-1)

This study has been transitioned to CTIS with ID 2023-505628-67-00 check the CTIS register for the current data. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult…

Characterizing tissue protein synthesis rates of non-small cell lung carcinomas in lung cancer patients

The current study aims to recruit a greater number of lung cancer patients to measure tissue protein synthesis rates of non-small cell lung carcinomas and healthy lung tissue. The protein synthesis rates of healthy lung tissue will be compared to…

A multicenter study of secukinumab, with a randomized double-blind, placebo-controlled withdrawal-retreatment period, to evaluate maintenance of response in participants with non-radiographic axial spondyloarthritis who achieved remission

This study has been transitioned to CTIS with ID 2023-509320-17-00 check the CTIS register for the current data. * To evaluate whether continuous secukinumab treatment is superior to placebo in preventing flares during Treatment Period 2 in…

A study comparing the effect and safety of once weekly dosing of somapacitan with daily Norditropin® as well as evaluating long-term safety of somapacitan in a basket study design in children with short stature either born small for gestational age or with Turner syndrome, Noonan syndrome, or idiopathic short stature

This study has been transitioned to CTIS with ID 2023-506927-27-00 check the CTIS register for the current data. Primary objectiveThe primary objective of this study is to confirm non-inferiority of once-weekly somapacitan compared with once-daily…

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral, covalent, menin inhibitor, in adult patients with acute leukemia (AL), diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), and chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL)

This study has been transitioned to CTIS with ID 2024-515744-23-00 check the CTIS register for the current data. The primary objectives of the study are to:Determine the OBD(s) and RP2D's) of BMF-219 monotherapy administered daily based on…

An Open-label Randomized Phase 3 Study of Tucatinib in Combination with Trastuzumab and mFOLFOX6 versus mFOLFOX6 given with or without either Cetuximab or Bevacizumab as First-line Treatment for Subjects with HER2+ Metastatic Colorectal Cancer

This study has been transitioned to CTIS with ID 2024-514180-25-00 check the CTIS register for the current data. To evaluate the efficacy and safety of tucatinib in combination with trastuzumab and mFOLFOX6 in comparison to mFOLFOX6 given with or…